Magnitude of Mycobacterium tuberculosis Infection and Its Resistance to Rifampicin Using Xpert-MTB/RIF Assay Among Presumptive Tuberculosis Patients at Motta General Hospital, Northwest Ethiopia

References

• Grange JM, Zumla A. The global emergency of tuberculosis: what is the cause? J R Soc Promot Health. 2002;122(2):78–81. doi:10.1177/14664240021220020612134771
   PubMedGoogle Scholar
• Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2(1):16076. doi:10.1038/nrdp.2016.7627784885
   PubMed Web of Science ®Google Scholar
• Adejumo OA, Daniel OJ, Otesanya AF, Salisu-Olatunj SO, Abdur-Razzaq HA. Evaluation of outcomes of tuberculosis management in private for profit and private-not-for profit directly observed treatment short course facilities in Lagos State, Nigeria. Niger Med J. 2017;58(1):44–49. doi:10.4103/0300-1652.21841729238128
   PubMedGoogle Scholar
• World Health Organazation (WHO). Global Tuberculosis Report. WHO; 2020.
   Google Scholar
• Zignol M, Dean AS, Falzon D, et al. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med. 2016;375(11):1081–1089. doi:10.1056/NEJMsr151243827626523
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-329276051
   PubMed Web of Science ®Google Scholar
• Drobniewski F, Nikolayevskyy V, Balabanova Y, Bang D, Papaventsis D. Diagnosis of tuberculosis and drug resistance: what can new tools bring us? [State of the art series. New tools. Number 1 in the series]. Int J Tuberc Lung Dis. 2012;16(7):860–870. doi:10.5588/ijtld.12.018022687497
   PubMed Web of Science ®Google Scholar
• Lawn SD, Wilkinson R. Extensively drug resistant tuberculosis. BMJ. 2006;333(7568):559–560. doi:10.1136/bmj.38971.587222.AB16973988
   PubMed Web of Science ®Google Scholar
• Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863. doi:10.1101/cshperspect.a01786325918181
   PubMed Web of Science ®Google Scholar
• Soini H, Vasankari T. MDR tuberculosis. Duodecim. 2014;130(16):1599–1605.25269365
   PubMedGoogle Scholar
• Raviglione MC. The new stop TB strategy and the global plan to stop TB, 2006–2015. Bull World Health Organ. 2007;85(5):327. doi:10.2471/BLT.06.03851317639210
   PubMed Web of Science ®Google Scholar
• Dessalegn M, Daniel E, Behailu S, Wagnew M, Nyagero J. Predictors of multidrug resistant tuberculosis among adult patients at Saint Peter Hospital Addis Ababa, Ethiopia. Pan Afr Med J. 2016;25(Suppl 2):5.
   Google Scholar
• Gelaw YA, Assefa Y, Soares Magalhaes RJ, et al. TB and HIV epidemiology and collaborative service: evidence from Ethiopia, 2011–2015. HIV/AIDS. 2020;12:839–847.
   Google Scholar
• Derbie A, Worku S, Mekonnen D, et al. Xpert MTB/RIF assay for the diagnosis of Mycobacterium tuberculosis and its rifampicin resistance at Felege Hiwot and Debre Tabor Hospitals, Northwest Ethiopia: a preliminary implementation research. Ethiop J Health Dev. 2016;30(2):60–66.
   Web of Science ®Google Scholar
• Li D, Song Y, Yang P, Li X, Zhang AM, Xia X. Genetic diversity and drug resistance of Mycobacterium tuberculosis in Yunnan, China. J Clin Lab Anal. 2019;33(5):e22884. doi:10.1002/jcla.2288430896073
   PubMed Web of Science ®Google Scholar
• Jaleta KN, Gizachew M, Gelaw B, Tesfa H, Getaneh A, Biadgo B. Rifampicin-resistant Mycobacterium tuberculosis among tuberculosis-presumptive cases at University of Gondar Hospital, northwest Ethiopia. Infect Drug Resist. 2017;10:185–192. doi:10.2147/IDR.S13593528652786
   PubMed Web of Science ®Google Scholar
• Gebretsadik D, Ahmed N, Kebede E, Mohammed M, Belete MA. Prevalence of tuberculosis by automated GeneXpert rifampicin assay and associated risk factors among presumptive pulmonary tuberculosis patients at Ataye District Hospital, North East Ethiopia. Infect Drug Resist. 2020;13:1507–1516. doi:10.2147/IDR.S24805932547120
   PubMed Web of Science ®Google Scholar
• Wasihun AG, Dejene TA, Hailu GG, Anupurba S. Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: a cross sectional study. PLoS One. 2020;15(11):e0240361. doi:10.1371/journal.pone.024036133147218
   PubMed Web of Science ®Google Scholar
• Derseh D, Moges F, Tessema B. Smear positive pulmonary tuberculosis and associated risk factors among tuberculosis suspects attending spiritual holy water sites in Northwest Ethiopia. BMC Infect Dis. 2017;17(1):100. doi:10.1186/s12879-017-2211-528125981
   PubMed Web of Science ®Google Scholar
• Sah SK, Bhattarai PR, Shrestha A, Dhami D, Guruwacharya D, Shrestha R. Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and associated factors among presumptive pulmonary tuberculosis patients in Nepal. Infect Drug Resist. 2020;13:2911–2919. doi:10.2147/IDR.S26379532903905
   PubMed Web of Science ®Google Scholar
• Charambira K, Ade S, Harries AD, et al. Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert(®) MTB/RIF in Zimbabwe. Public Health Action. 2016;6(2):122–128. doi:10.5588/pha.16.000527358806
   PubMedGoogle Scholar
• Yohanes A, Abera S, Ali S. Smear positive pulmonary tuberculosis among suspected patients attending metehara sugar factory hospital; eastern Ethiopia. Afr Health Sci. 2012;12(3):325–330. doi:10.4314/ahs.v12i3.1223382747
   PubMed Web of Science ®Google Scholar
• Zewdie O, Dabsu R, Kifle E, Befikadu D. Rifampicin-resistant multidrug-resistant tuberculosis cases in selected hospitals in Western Oromia, Ethiopia: cross-Sectional Retrospective Study. Infect Drug Resist. 2020;13:3699–3705. doi:10.2147/IDR.S27458933116690
   PubMed Web of Science ®Google Scholar
• Arega B, Menbere F, Getachew Y. Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia. BMC Infect Dis. 2019;19(1):307. doi:10.1186/s12879-019-3943-130947695
   PubMed Web of Science ®Google Scholar
• Ejeta E, Beyene G, Bonsa Z, Abebe G. Xpert MTB/RIF assay for the diagnosis of Mycobacterium tuberculosis and Rifampicin resistance in high human immunodeficiency virus setting in Gambella regional state, southwest Ethiopia. J Clin Tuberc Other Mycobact Dis. 2018;12:14–20. doi:10.1016/j.jctube.2018.06.00231720393
   PubMedGoogle Scholar
• Gebrehiwet GB, Kahsay AG, Welekidan LN, Hagos AK, Abay GK, Hagos DG. Rifampicin resistant tuberculosis in presumptive pulmonary tuberculosis cases in Dubti Hospital, Afar, Ethiopia. J Infect Dev Ctries. 2019;13(1):21–27. doi:10.3855/jidc.1046232032019
   PubMed Web of Science ®Google Scholar
• Tilahun M, Ameni G, Desta K, et al. Molecular epidemiology and drug sensitivity pattern of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in and around Ambo Town, Central Ethiopia. PLoS One. 2018;13(2):e0193083. doi:10.1371/journal.pone.019308329447273
   PubMed Web of Science ®Google Scholar
• Mulu W, Abera B, Yimer M, Hailu T, Ayele H, Abate D. Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study. BMC Res Notes. 2017;10(1):8. doi:10.1186/s13104-016-2328-428057041
   PubMedGoogle Scholar
• Bodena D, Ataro Z, Tesfa T. Trend analysis and seasonality of tuberculosis among patients at the Hiwot Fana Specialized University Hospital, Eastern Ethiopia: a Retrospective Study. Risk Manag Healthc Policy. 2019;12:297–305. doi:10.2147/RMHP.S22865931849546
   PubMed Web of Science ®Google Scholar
• Jarallah JS, Elias AK, Al Hajjaj MS, Bukhari MS, Al Shareef AH, al-Shammari SA. High rate of rifampicin resistance of Mycobacterium tuberculosis in the Taif region of Saudi Arabia. Tuber Lung Dis. 1992;73(2):113–115. doi:10.1016/0962-8479(92)90065-R1643296
   PubMedGoogle Scholar
• Coovadia YM, Mahomed S, Pillay M, Werner L, Mlisana K, Nicol MP. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region. PLoS One. 2013;8(11):e77712. doi:10.1371/journal.pone.007771224223122
   PubMed Web of Science ®Google Scholar
• Adane K, Ameni G, Bekele S, Abebe M, Aseffa A. Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia. BMC Public Health. 2015;15(1):572. doi:10.1186/s12889-015-1933-926092570
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Paramasivan CN, Ponnuraja C, Iliayas S, Rajasekaran S, Narayanan PR. Anti-tuberculosis drug resistance in patients with HIV and tuberculosis in South India. Int J Tuberc Lung Dis. 2005;9(8):896–900.16104637
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines Approved by the Guidelines Review Committee. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization; 2014.
   Google Scholar